<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Nilotinib; Tasigna" /><meta name="IX" content="Nilotinib; Tasigna" /><title>Tasigna®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5541-tasigna.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5541-tasigna.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5541-tasigna.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 08 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a> &gt; <a href="PHP5514-protein-kinase-inhibitors.htm">Protein kinase inhibitors</a> &gt; <a href="PHP5540-nilotinib.htm">NILOTINIB</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5538-lapatinib.htm" title="Previous: LAPATINIB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5542-pazopanib.htm" title="Next: PAZOPANIB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a308017.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Nilotinib</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/24634-x.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Nilotinib</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: N &gt; Interactions of Nilotinib</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="PHP5514-protein-kinase-inhibitors.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Protein kinase inhibitors</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs</p></div></li><li><a href="PHP5540-nilotinib.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">NILOTINIB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Protein kinase inhibitors</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-24634-x.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Nilotinib</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-N35.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Nilotinib Hydrochloride Monohydrate</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; N</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E26E3E0R0D383.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Nilotinib</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; N</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>NILOTINIB</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int1118-nilotinib.htm">Nilotinib</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT"> see <a title="target-block: Nilotinib notes " href="PHP5514-protein-kinase-inhibitors.htm#PHP5521">notes above</a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="section: Cytotoxic drugs" href="PHP5180-cytotoxic-drugs.htm">section 8.1</a>; history of pancreatitis; susceptibility to QT-interval prolongation (including electrolyte disturbances, concomitant use of drugs that prolong QT interval); <strong>interactions:</strong> Appendix 1 (nilotinib)</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Hepatic impairment </h2> <p class="cT">manufacturer advises caution</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">manufacturer advises avoid unless potential benefit outweighs risk—toxicity in <em>animal</em> studies; effective contraception required during treatment; see also <a title="target-block: Cytotoxic drugs: Reproductive function" href="PHP5183-side-effects-of-cytotoxic-drugs.htm#PHP5194">Pregnancy and Reproductive Function</a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">manufacturer advises avoid—present in milk in <em>animal</em> studies</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">see <a title="topic: Side-effects of cytotoxic drugs" href="PHP5183-side-effects-of-cytotoxic-drugs.htm">section 8.1</a>; also abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, anorexia, weight changes; palpitation, QT-interval prolongation, hypertension, oedema, flushing; dyspnoea, cough, dysphonia; headache, fatigue, asthenia, dizziness, paraesthesia, insomnia, vertigo; hypomagnesaemia, hyperkalaemia, blood glucose changes; bone pain, arthralgia, muscle spasm; urticaria, erythema, hyperhidrosis, dry skin, rash, pruritus; <em>less commonly</em> hepatitis, pancreatitis, dry mouth, chest pain, cardiac failure, arrhythmias, pericardial effusion, coronary artery disease, cardiomegaly, cardiac murmur, bradycardia, hypertensive crisis, haemorrhage, melaena, haematoma, pleural effusion, interstitial lung disease, migraine, hypoaesthesia, hyperaesthesia, depression, anxiety, tremor, influenza-like symptoms, hyperthyroidism, breast pain, gynaecomastia, erectile dysfunction, dysuria, urinary frequency, hypokalaemia, hyponatraemia, hypocalcaemia, hypophosphataemia, dehydration, decreased visual acuity, conjunctivitis, dry eyes, epistaxis, and ecchymosis</p></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul><li><p>Newly diagnosed chronic myeloid leukaemia, chronic phase, <span class="cP">adult</span> over 18 years, 300 mg twice daily</p></li> <li><p>Chronic and accelerated phase chronic myeloid leukaemia (see notes above), <span class="cP">adult</span> over 18 years, 400 mg twice daily</p></li> </ul></div></div> </div><div id="pS"><p>Sub-sections</p><div id="PHP5541-tasigna" style="margin: 0 0 0 20px;"><h1 class="title">Tasigna® <span>(<a href="PHP10005-index-of-manufacturers.htm#PHP10261">Novartis</a>)</span><span> <a title="Report adverse reaction(s)" href="PHP10518-yellow-card-scheme.htm"><img class="cD" src="images/blacktri_s.png" alt="Report adverse reaction(s)" /></a> <img src="images/pom_l.png" alt="Prescription only medicine" /></span></h1><div class="cU"><p><strong>Capsules</strong>, nilotinib (as hydrochloride monohydrate) 150 mg (red), net price 112-cap pack = £2432.85; 200 mg (yellow), 112-cap pack = £2432.85. Label: 23, 25, 27</p></div></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5538-lapatinib.htm">Previous: LAPATINIB</a> | <a class="top" href="PHP5541-tasigna.htm#">Top</a> | <a accesskey="]" href="PHP5542-pazopanib.htm">Next: PAZOPANIB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>